Welcome to our dedicated page for Gossamer Bio news (Ticker: GOSS), a resource for investors and traders seeking the latest updates and insights on Gossamer Bio stock.
Gossamer Bio, Inc. (NASDAQ: GOSS) is a late-stage, clinical biopharmaceutical company centered on the development and commercialization of seralutinib for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD). The GOSS news feed on Stock Titan brings together company announcements, scientific updates, financial disclosures, and corporate developments that shape the investment and clinical narrative around its pulmonary hypertension programs.
News items for Gossamer Bio frequently cover progress in its registrational Phase 3 trials, including the PROSERA Study in PAH and the SERANATA Study in PH‑ILD. Investors and observers can follow updates on enrollment milestones, planned timelines for topline data, and key clinical endpoints such as six‑minute walk distance (6MWD), time to clinical worsening, and lung function measures. Scientific conference coverage, such as presentations at the European Respiratory Society (ERS) Congress, provides additional context on seralutinib’s mechanistic and translational data.
The GOSS news stream also reflects Gossamer Bio’s broader corporate and pipeline activities. This includes quarterly financial results and business updates, collaboration news with the Chiesi Group, stockholder meeting outcomes, and announcements related to its option agreement to acquire Respira Therapeutics and the investigational inhaled vardenafil candidate RT234. Regular disclosures of employment inducement stock option grants highlight hiring and equity compensation practices under Nasdaq Listing Rule 5635(c)(4).
By monitoring Gossamer Bio news on Stock Titan, readers can track how clinical data, regulatory milestones, scientific presentations, financial performance, and strategic transactions interact within the company’s focused pulmonary hypertension strategy. This page is intended as a central hub for GOSS-related headlines and press releases, helping users follow the evolution of its late-stage programs over time.
Gossamer Bio, a clinical-stage biopharmaceutical company, announced the approval of non-qualified stock option awards for five new non-executive employees. The Compensation Committee of Gossamer's Board of Directors granted options to purchase up to 221,000 shares of the company's common stock under the 2023 Employment Inducement Incentive Award Plan. These awards, granted on October 4, 2024, are in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of $1.07 per share, equal to the closing price of Gossamer's common stock on the grant date. They have a ten-year term and will vest over four years, with 25% vesting on the one-year anniversary and the remainder vesting in 36 monthly installments, subject to continued employment.
Gossamer Bio (Nasdaq: GOSS) announced data presentations for seralutinib at the European Respiratory Society (ERS) Congress 2024 in Vienna. The presentations include additional findings from the Phase 2 TORREY open-label extension study, highlighting sustained effects of seralutinib beyond 24 weeks in treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
The data demonstrates continued improvement in clinical outcome measures and sustained effects on circulating biomarkers relevant to PAH pathogenesis. Two oral presentations and one poster presentation will showcase seralutinib's potential in making a meaningful difference for patients with pulmonary hypertension.
Gossamer Bio (GOSS) reported strong Q2 2024 financial results, highlighting a cash position of $354.5 million as of June 30, 2024. The company's focus remains on developing seralutinib for PAH and PH-ILD treatment. Key developments include:
1. Ongoing enrollment in the PROSERA Study, a Phase 3 trial for PAH, with topline results expected in Q4 2025.
2. Plans to start a Phase 3 trial for PH-ILD in mid-2025.
3. A collaboration with Chiesi Group for seralutinib development and commercialization.
4. Q2 revenue of $95.9 million, including $88.8 million from license sales.
5. Net income of $49.2 million, or $0.22 per share, compared to a net loss in Q2 2023.
The company expects its current cash position to fund operations into the first half of 2027.
Gossamer Bio (Nasdaq: GOSS), a clinical-stage biopharmaceutical firm, has announced an inducement grant under Nasdaq Listing Rule 5635(c)(4). The Compensation Committee of Gossamer's Board approved non-qualified stock options for a new non-executive employee, effective June 5, 2024. The grant includes options to purchase up to 170,000 shares at an exercise price of $0.57 per share, equivalent to the closing price on the Nasdaq Global Select Market on that date. These options have a ten-year term and will vest over four years: 25% after one year, with the remaining shares vesting in 36 monthly installments. These inducement awards aim to attract new talent under Gossamer's 2023 Employment Inducement Incentive Award Plan.
Gossamer Bio (Nasdaq: GOSS), a clinical-stage biopharmaceutical company, will present updated data on seralutinib at the American Thoracic Society 2024 International Conference from May 17-22 in San Diego.
The presentations will include interim results from the Phase 1B and Phase 2 TORREY open-label extension study in pulmonary arterial hypertension (PAH) and additional data on circulating biomarkers, inflammation, and fibrosis. The main presentation will be on May 19 by Dr. Olivier Sitbon.
Gossamer Bio, Inc. (NASDAQ: GOSS) granted non-executive employees stock options under the 2023 Inducement Plan. The options allow the purchase of up to 323,000 shares at $0.755 per share, vesting over four years. This grant aims to incentivize and retain new employees in accordance with Nasdaq rules.
Gossamer Bio, Inc. (Nasdaq: GOSS) announced its first quarter 2024 financial results and business update. The company reported $396 million in cash, pro forma for a $160 million reimbursement payment and debt repayment. They are collaborating with Chiesi for seralutinib development and co-commercialization. The PROSERA Phase 3 study for PAH is ongoing, with top-line results expected in Q4 2025. A registrational Phase 3 study for PH-ILD is set to begin in mid-2025. TORREY Phase 2 PAH results were published in Lancet Respiratory Medicine, with additional data to be presented at ATS in May.
Gossamer Bio and Chiesi Group have announced a global collaboration to develop and commercialize Seralutinib for pulmonary hypertension. Gossamer will receive development reimbursement and milestones payments, leading the US commercialization activities. Chiesi obtains exclusive ex-US commercial rights with Gossamer receiving royalties on net sales. A Phase 3 trial of Seralutinib in PH-ILD is planned for mid-2025.
Gossamer Bio, Inc. announced the publication of the TORREY Phase 2 study results in the Lancet Respiratory Medicine, showcasing the positive impact of seralutinib in treating pulmonary arterial hypertension. The study demonstrated significant improvements in pulmonary vascular resistance and other key disease measures. This milestone sets the stage for the Phase 3 PROSERA Study, highlighting the potential of seralutinib to enhance the quality of life for PAH patients.
Summary not available.